• 1
    Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361: 9018.
  • 2
    Kovalevsky G, Gracia CR, Berlin JA, Sammel MD, Barnhart KT. Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss. Arch Intern Med 2004; 164: 55863.
  • 3
    Dudding TE, Attia J. The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta-analysis. Thromb Haemost 2004; 91: 70011.
  • 4
    Roqué H, Paidas MJ, Funai EF, Kuczynski E, Lockwood CJ. Maternal thrombophilias are not associated with early pregnancy loss. Thromb Haemost 2004; 91: 2905.
  • 5
    Gris JC, Quéré I, Sanmarco M, Boutière B, Mercier E, Amiral J, Hubert AM, Ripart-Neveu S, Hoffet M, Tailland ML, Rousseau O, Montpeyroux F, Dauzat M, Sampol J, Daurès JP, Berlan J, Marès P. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nîmes Obstetricians and Haematologists study4. Thromb Haemost 2000; 84: 22836.
  • 6
    Hézard N, Cornillet-Lefebvre P, Gillot L, Potron G, Nguyen P. Multiplex ASA PCR for a simultaneous determination of factor V Leiden gene, G > A 20210 protrombin gene and C > T 677 MTHFR gene mutations. Thromb Haemost 1998; 79: 10545.
  • 7
    Miler JR, Williamson E, Glue J, Gordon YB, Grudzinskas JG, Sikes A. Fetal loss after implantation: a prospective study. Lancet 1980; ii: 5546.
  • 8
    Edmonds DK, Lindsay KS, Miller JR, Williamson E, Wood PJ. Early embryonic mortality in women. Fertil Steril 1982; 38: 44753.
  • 9
    Whittaker PG, Taylor A, Lind T. Unexpected pregnancy loss in healthy women. Lancet 1983; i: 11267.
  • 10
    Wilcox AJ, Weinberg CR, O'Connor JF, Baird DD, Schlatterer JP, Canfield RE, Amstrong EG, Nisula BC. Incidence of early loss in pregnancy. N Engl J Med 1988; 319: 18994.
  • 11
    Gindler J, Li Z, Berry RJ, Zheng JC, Correa A, Sun XM, Wong LY, Cheng LC, Erickson JD, Wang Y, Tong QL. Folic acid supplements during pregnancy and risk of miscarriage. Lancet 2001; 358: 796800.
  • 12
    Maconochie N, Doyle P, Prior S. The National Women's Health Study: assembly and description of a population-based reproductive cohort. BMC Public Health 2004; 4: 35.
  • 13
    Anderson AM, Wohlfahrt J, Christens P, Olsen J, Melbye M. Maternal age and fetal loss: population based register linkage study. Br Med J 2000; 320: 170812.
  • 14
    Lashen H, Fear K, Sturdee DW. Obesity is associated with increased risk of first trimester and recurrent miscarriage: matched case-control study. Hum Reprod 2004; 19: 16446.
  • 15
    Ness RB, Grisso JA, Hirschinger N, Markovis N, Shaw LM, Day NL, Kline J. Cocaine and tobacco use and the risk of spontaneous abortion. N Engl J Med 1999; 340: 3339.
  • 16
    George L, Mills JL, Johansson AL, Nordmark A, Olander B, Granath F, Cnattingins S. Plasma folate levels and risk of spontaneous abortion. JAMA 2002; 288: 186773.
  • 17
    Signorello LB, McLaughlin JK. Maternal caffeine consumption and spontaneous abortion: a review of the epidemioloc evidence. Epidemiology 2004; 15: 22939.
  • 18
    Henriksen TB, Hjollund NH, Jensen TK, Bonde JP, Anderson AM, Kolstad H, Ernst E, Giwercunan A, Skakkebaek NE, Olsen J. Alcohol consumption at the time of conception and spontaneous abortion. Am J Epidemiol 2004; 160: 6617.
  • 19
    Ford JH, MacCormac L. Pregnancy lifestyle study: the long-term use of contraceptive pill and the risk of age-related miscarriage. Hum Reprod 1995; 10: 1397402.
  • 20
    Cattaruzza MS, Spinelli A. Spontaneous abortion in Italy: social differences and temporal trends. Epidemiol Prev 2000; 24: 16671.
  • 21
    Hemminki E, Merilainen J, Malin M, Rahkonen O, Teperi J. Mother's education and perinatal problems in Finland. Int J Epidemiol 1992; 21: 7204.
  • 22
    Sun Y, Che Y, Gao E, Olsen J, Zhou W. Induced abortion and risk of subsequent miscarriage. Int J Epidemiol 2003; 32: 44954.
  • 23
    Chen A, Yuan W, Meirik O, Wang X, Wu SZ, Zhou L, Luo L, Gao E, Cheng Y. Mifepristone-induced early abortion and outcome of subsequent wanted pregnancy. Am J Epidemiol 2004; 160: 1107.
  • 24
    Chafa O, Reghis A, Aubert A, Fisher AM. Prevalence of the FVQ506 (factor V Leiden) mutation in the normal and thrombophilic Algerian population. Br J Haematol 1997; 97: 6889.
  • 25
    Mathonnet F, Nadifi S, Serazin-Leroy V, Dakouane M, Giudicelli Y. Absence of factor V Leiden mutation and low prothrombin G20210A mutation prevalence in a healthy Moroccan population. Thromb Haemost 2002; 88: 10734.
  • 26
    Lucotte G, Mercier G. Population genetics of factor V Leiden in Europe. Blood Cells Mol Dis 2001; 27: 3627.
  • 27
    Rosendaal FR, Dogen CJ, Zivelin A, Aruda VR, Aiach M, Siscovick DS, Hillarp A, Watzke HH, Bernardi F, Cumming AM, Preston FE, Reitsma PH. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998; 79: 7068.
  • 28
    Boyd JD. Development of the human placenta with the first three months of gestation. J Anat Lond 1960; 94: 297328.
  • 29
    Makikallio K, Tekay A, Jouppila P. Yolk sac and umbilicoplacental hemodynamics during early human embryonic development. Ultrasound Obstet Gynecol 1999; 14: 1759.
  • 30
    Isermann B, Sood R, Pawlinski R, Zogg M, Kalloway S, Degen JL, Mackman N, Weiler H. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med 2003; 9: 3317.
  • 31
    Gris JC, Mercier E, Quéré I, Lavigne-Lissalde G, Cochery-Nouvellon E, Hoffet M, Ripart-Neveu S, Tailland ML, Dauzat M, Marès P. Low molecular weight heparin versus low-dose aspirin in women with one foetal loss and a constitutional thrombophilic disorder. Blood 2004; 103: 36959.